Last reviewed · How we verify
Lipid-lowering treatments
At a glance
| Generic name | Lipid-lowering treatments |
|---|---|
| Sponsor | Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC (PHASE1)
- Metformin Safety and Efficacy in Osteoarthritis. (PHASE3)
- The Belgian REAL (BE.REAL) Registry
- Optimizing Non-statin Agents for ASCVD
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: